Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Qiagen launches H1N1 test globally

This article was originally published in Clinica

Executive Summary

Qiagen has launched its artus Influenza/H1 RG/LC RT-PCR Kit, designed to detect the H1N1 virus, worldwide. The test, which provides results in around 40 minutes, "currently has no official US FDA approval or CE marking", a spokesperson for Qiagen told Clinica. However, the firm is "evaluating its options and wouldn't exclude this possibility in the future". The first customer to order the test is the government of Saudi Arabia. Qiagen (Venlo, the Netherlands) claims the diagnostic can detect H1N1 and other influenza A and B strains. Other PCR-based tests can take up to 24 hours to carry out, but rapid, antibody-based tests have been criticised for lacking sensitivity.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT044243

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel